Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 753 results for adult social

  1. Positive workplaces for social workers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social...

  2. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  3. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

  4. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  5. What is the effectiveness, cost effectiveness and acceptability of social prescribing for carers?

    Question What is the effectiveness, cost effectiveness and acceptability of social prescribing for carers? Any explanatory notes(if...

  6. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  7. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  8. Retaining social workers

    NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive...

  9. Investing in line managers

    NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive...

  10. The role of families in supporting young adults discharged from children's services:- What is the most effective way of helping families to support young people who have been discharged from children's services (whether or not they meet criteria for adult services)?

    NG43/2 Question The role of families in supporting young adults discharged from children's services:- What is the most effective way of

  11. Ensuring positive organisational change practices

    NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive...

  12. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

  13. Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  14. Sarcoma (QS78)

    This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.

  15. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.